Autolus Therapeutics plc

AUTL · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
116
SEC Filings

Business Summary

PART I Business Overview We are an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune diseases. Using our broad suite of proprietary and modular T cell programming technologies, we are engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate target cells. We bel...

Next Earnings

Q2 FY2026 — expected 2026-08-15

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionAUTLdiscussed_in_filing Cybersecurity
topic_mentionAUTLdiscussed_in_filing Trusted Computing
topic_mentionAUTLdiscussed_in_filing Blockchain & Crypto
topic_mentionAUTLdiscussed_in_filing Supply Chain
topic_mentionAUTLdiscussed_in_filing Regulation
topic_mentionAUTLdiscussed_in_filing Healthcare & Bio
topic_mentionAUTLdiscussed_in_filing Platform & Ecosystem
topic_mentionAUTLdiscussed_in_filing Sovereign & Government
topic_mentionAUTLdiscussed_in_filing Cybersecurity
topic_mentionAUTLdiscussed_in_filing Trusted Computing
topic_mentionAUTLdiscussed_in_filing Blockchain & Crypto
topic_mentionAUTLdiscussed_in_filing Supply Chain
topic_mentionAUTLdiscussed_in_filing Regulation
topic_mentionAUTLdiscussed_in_filing Healthcare & Bio
topic_mentionAUTLdiscussed_in_filing Platform & Ecosystem
topic_mentionAUTLdiscussed_in_filing Sovereign & Government
topic_mentionAUTLdiscussed_in_filing Cybersecurity
topic_mentionAUTLdiscussed_in_filing Trusted Computing
topic_mentionAUTLdiscussed_in_filing Blockchain & Crypto
topic_mentionAUTLdiscussed_in_filing Supply Chain

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-272025-12-310001730463-26-000038EDGAR145K words
2025-03-202024-12-310001730463-25-000019EDGAR—
2024-03-212023-12-310001730463-24-000048EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-122025-09-300001730463-25-000088EDGAR33K words
2025-08-122025-06-300001730463-25-000067EDGAR—
2025-05-082025-03-310001730463-25-000039EDGAR—
2024-11-122024-09-300001730463-24-000136EDGAR—
2024-08-082024-06-300001730463-24-000093EDGAR—
2024-05-172024-03-310001730463-24-000064EDGAR—
2023-11-092023-09-300001730463-23-000110EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-270001730463-26-000032EDGAR1K words
2026-01-260001730463-26-000019EDGAR—
2026-01-120001730463-26-000012EDGAR—
2025-12-020001730463-25-000095EDGAR—
2025-11-120001730463-25-000081EDGAR—
2025-08-120001730463-25-000064EDGAR—
2025-06-270001730463-25-000046EDGAR—
2025-06-020001730463-25-000043EDGAR—
2025-05-300001193125-25-132111EDGAR—
2025-05-080001730463-25-000032EDGAR—

116 total filings indexed. 96 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001730463
TickerAUTL
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedX0

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: f2fdb3a993fe139e02bc927763d600f9938ec6e38b23cdbbe6090ed4964ae976
parent: 51f10ac5653059352dabc58a33105113b9975fcac765183cca4959610372e449
content hash: 7c9e6b2e6bd21df9dcb16095d76003a97c6119cebc900d6c8ba39ba025e1e919
signed: 2026-04-13T04:43:48.542Z
sources: 10 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf